SUBSCRIBE
SUBSCRIBE

GSK Bio

NEWS
3 Biotechs That Could be Taken Out This Quarter
Deals
Drug Giants Making Googly Eyes At 2 Small Biotechs
September 21, 2017
 · 
3 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Former GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms
September 19, 2017
 · 
2 min read
Ionis Pharma Urges Investors to Reject the Below-the-Market Offer By TRC Capital
Deals
Ionis Pharma Urges Investors to Reject the Below-the-Market Offer By TRC Capital
August 24, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Bay
3 Hot Biotech Stocks That Cost Less than a Cup of Coffee
August 21, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Gained $1 Billion Overnight After Becoming Goldman Sachs’ Favorite Biotech
August 17, 2017
 · 
3 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Business
Novartis AG Lures Superstar Scientist Away From UCSF
August 17, 2017
 · 
3 min read
Ionis Pharma Urges Investors to Reject the Below-the-Market Offer By TRC Capital
Business
GlaxoSmithKline Ditches Ionis Pharma’s Inotersen and IONIS-FB-LRx
August 11, 2017
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Policy
Gilead’s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down
August 11, 2017
 · 
3 min read
Boy Wonder Ramaswamy's Roivant Bets $116 Million on Arbutus
Happy Birthday, Vivek Ramaswamy—Here’s a $1.1 Billion Present
August 9, 2017
 · 
2 min read
Load More
  • 2026 - Best Places to Work - Badge (1).png
JOBS
IN THE PRESS
Press Releases
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
 · 
9 min read
Press Releases
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
November 12, 2024
 · 
4 min read
Press Releases
Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk
November 5, 2024
 · 
7 min read
Press Releases
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 8, 2024
 · 
10 min read
Pharm Country
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 7, 2024
 · 
5 min read
Pharm Country
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
 · 
6 min read
Deals
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
 · 
7 min read
Business
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 2, 2022
 · 
5 min read